MitoRestore Pharmaceuticals is a clinical-stage biotechnology company focused on developing mitophagy-inducing therapeutics for neurodegenerative diseases, with an initial focus on Parkinson's disease. Founded in 2020 and headquartered in San Diego, California, MitoRestore is pioneering approaches to restore the cellular mitophagy pathway that is defective in most forms of PD[1].
The company's lead program, MR-201, is a small molecule PINK1 activator designed to restore mitophagy—the cellular process that clears damaged mitochondria—directly addressing one of the fundamental pathogenic mechanisms in Parkinson's disease.
The mitophagy pathway is critically impaired in Parkinson's disease:
MR-201 is a first-in-class PINK1 activator that works through multiple mechanisms:
| Drug | Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| MR-201 | PINK1 activator | Parkinson's Disease | Phase 1 | Active |
| MR-301 | Autophagy enhancer | PD with GBA mutations | Preclinical | IND-enabling |
| MR-401 | Mitochondrial biogenesis | Age-related neurodegeneration | Discovery | Research |
Phase 1a (2024): First-in-human study in healthy volunteers demonstrated safety and target engagement. The study measured:
Phase 1b (2025): Multiple dose study in early PD patients (Hoehn & Yahr stages 1-3) is evaluating:
| Parameter | Value |
|---|---|
| Design | Randomized, double-blind, placebo-controlled |
| Patients | Early PD (n=36) |
| Dose groups | 25mg, 50mg, 100mg |
| Duration | 28 days treatment |
In Drosophila with PINK1 loss-of-function mutations, MR-201:
| Attribute | Details |
|---|---|
| Headquarters | San Diego, California, USA |
| Founded | 2020 |
| CEO | Dr. Michael Torres |
| CSO | Dr. Jennifer Nakamura |
| Funding | Series A ($25M, 2021), Series B ($55M, 2024) |
| Investors | OrbiMed, RA Capital, MPM Capital |
MitoRestore maintains partnerships with leading research institutions:
MitoRestore's development strategy prioritizes:
Future development may explore:
| Company | Drug | Mechanism | Stage |
|---|---|---|---|
| MitoRestore | MR-201 | PINK1 activator | Phase 1 |
| Denali | DNL151 | LRRK2 inhibitor | Phase 2 |
| Prevail | PR001 | AAV-GBA1 | Phase 1/2 |
| Gain Therapeutics | GT-02287 | GCase activator | Preclinical |